Company profile SMMT

Summit Therapeutics Inc
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Quarter analysis & expected interestLast update: February 09 2024 18:47:13.

After 39 days of this quarter the interest is at 229.0. Based on that we can calculate that during remaining 52 days it will total up to 534.0.
Summit Therapeutics -stock expected interest is significantly higher compared to previous quarter (+79.2%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019137
127
-7.3% QoQ
169
33.1% QoQ
132
-21.9% QoQ
2020 172
25.5% YoY 30.3% QoQ
152
19.7% YoY -11.6% QoQ
145
-14.2% YoY -4.6% QoQ
213
61.4% YoY 46.9% QoQ
2021 136
-20.9% YoY -36.2% QoQ
133
-12.5% YoY -2.2% QoQ
267
84.1% YoY 100.8% QoQ
238
11.7% YoY -10.9% QoQ
2022 253
86.0% YoY 6.3% QoQ
251
88.7% YoY -0.8% QoQ
223
-16.5% YoY -11.2% QoQ
266
11.8% YoY 19.3% QoQ
2023 390
54.2% YoY 46.6% QoQ
383
52.6% YoY -1.8% QoQ
255
14.3% YoY -33.4% QoQ
298
12.0% YoY 16.9% QoQ
2024 229
-41.3% YoY -23.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Summit Therapeutics -stock search interestLast update: February 09 2024 18:47:12.
Correlation coefficient between keyword and revenue is -0.05
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 18:47:16.

The average 5 years interest of Summit Therapeutics -stock was 17.51 per week.
The last year interest of Summit Therapeutics -stock compared to the last 5 years has changed by 47.29%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 117.09%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics biopharmaceutical to provide analysis

Correlation between past revenue and Summit Therapeutics biopharmaceutical search interest

There is not enough data for Summit Therapeutics biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics Cambridge Massachusetts to provide analysis

Correlation between past revenue and Summit Therapeutics Cambridge Massachusetts search interest

There is not enough data for Summit Therapeutics Cambridge Massachusetts to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics Cambridge Massachusetts to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SMMT precision antibiotics to provide analysis

Correlation between past revenue and SMMT precision antibiotics search interest

There is not enough data for SMMT precision antibiotics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SMMT precision antibiotics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SMMT multidrug resistant infections to provide analysis

Correlation between past revenue and SMMT multidrug resistant infections search interest

There is not enough data for SMMT multidrug resistant infections to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SMMT multidrug resistant infections to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics pipeline to provide analysis

Correlation between past revenue and Summit Therapeutics pipeline search interest

There is not enough data for Summit Therapeutics pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics collaboration Akeso to provide analysis

Correlation between past revenue and Summit Therapeutics collaboration Akeso search interest

There is not enough data for Summit Therapeutics collaboration Akeso to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics collaboration Akeso to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics oncology therapies to provide analysis

Correlation between past revenue and Summit Therapeutics oncology therapies search interest

There is not enough data for Summit Therapeutics oncology therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics oncology therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for SMMT carbapenem-resistant Enterobacteriaceae infections to provide analysis

Correlation between past revenue and SMMT carbapenem-resistant Enterobacteriaceae infections search interest

There is not enough data for SMMT carbapenem-resistant Enterobacteriaceae infections to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for SMMT carbapenem-resistant Enterobacteriaceae infections to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Summit Therapeutics headquarters Cambridge to provide analysis

Correlation between past revenue and Summit Therapeutics headquarters Cambridge search interest

There is not enough data for Summit Therapeutics headquarters Cambridge to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Summit Therapeutics headquarters Cambridge to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for SMMT
Earnings date: 2024-03-07 Before open
Company name: Summit Therapeutics Inc
Sector:
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-22T10:00:00Z

BusinessWire
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

2026-10-21T08:42:00-04:00

PR Newswire
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

2026-10-21T10:05:00Z

BusinessWire
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

2026-10-19T11:00:00Z

BusinessWire
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

2026-10-05T19:44:30+0000

CNBC
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

2026-10-05T11:00:00Z

BusinessWire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

2026-10-02T11:13:23+0000

CNBC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

2026-10-02T06:30:00Z

BusinessWire
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

2026-10-02T06:30:00Z

BusinessWire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

2026-10-01T12:53:40.004996199Z

Analyst Upgrades
Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

2026-09-29T17:52:31.132747455Z

Analyst Upgrades
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43

2026-09-28T21:30:00Z

BusinessWire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

2026-09-23T11:04:13.31826425Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

2026-09-22T10:00:00Z

BusinessWire
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

2026-09-15T10:00:00Z

BusinessWire
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients